Teva Pharm CEO calls on Trump for faster US drug approvals
U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...
Teva CEO responds to 25% share price fall
Teva CEO Richard Francis said that he had not expected such a harsh reaction from the market but he sees a positive side to ...
FiercePharma8d
Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Holdings Decreased by abrdn plc
Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 15.0% during the 4th quarter, according to its most ...
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...
Teva Pharmaceutical Industries Full Year 2024 Earnings: EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Looking ahead, ...
ETF Daily News7d
Analysts Set Teva Pharmaceutical Industries Limited (NYSE:TEVA) PT at $23.57
Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, analysts forecast that Teva Pharmaceutical Industries will post 2.62 EPS ...